Table 1 Characteristics of the RNAseq, mass spectrometry, and flow cytometry cohorts
From: Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
Bulk RNAseq | Single cell RNAseq | Mass spectrometry | Flow cytometry | |
|---|---|---|---|---|
Number | 85 | 22 | 9 | 52 |
Median age at diagnosis (months) | 20.7 | 24.8 | 9.1 | 20.3 (50 with data) |
Range | 0.9–303.5 | 1–86.8 | 0.8–70.5 | 0.8–98.4 |
Gender | ||||
Male | 51/83 (61.4%) | 16/22 (72.7%) | 4/9 (44.4%) | 30/51 (58.8%) |
Female | 32/83 (38.6%) | 6/22 (27.3%) | 5/9 (55.6%) | 21/51 (41.2%) |
Elevated fetal hemoglobin for age | 37/68 (54.4%) | 12/17 (70.6%) | 4/8 (50%) | 25/42 (59.5%) |
Median platelet count at diagnosis (109/L) | 55 (75 with data) | 96.5 (20 with data) | 76.0 | 50 (44 with data) |
Range | 5–297 | 15–223 | 26–161 | 8–223 |
Number of somatic mutations at diagnosis | ||||
Mean | 1.4 | 1.8 | 1.4 | 1.4 (50 with data) |
1 | 56/85 (65.9%) | 10/22 (45.5%) | 6/9 (66.7%) | 34/50 (68%) |
≥2 | 27/85 (31.8%) | 12/22 (54.5%) | 3/9 (33.3%) | 16/50 (32%) |
Methylation category | ||||
Low | 32/59 (54.2%) | 6/17 (35.3%) | 4/8 (50%) | 13/29 (44.8%) |
Intermediate | 8/59 (13.6%) | 2/17 (11.8%) | 0/8 (0%) | 1/29 (3.4%) |
High | 19/59 (32.2%) | 9/17 (52.9%) | 4/8 (50%) | 15/29 (51.7%) |
